Pharmaxis awarded A$1 million to progress Duchenne Muscular Dystrophy drug into the clinic

Pharmaxis awarded A$1 million to progress Duchenne Muscular Dystrophy drug into the clinic

Proactive Investors

Published

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) has been awarded A$1 million in Australian Government funding to advance work on the company's drug discovery for the treatment of the devastating genetic disorder Duchenne Muscular Dystrophy (DMD).

The government matched funding under the Biomedical Translation Bridge (BTB) program will allow Pharmaxis to take another one of its pipeline of amine oxidase inhibitors (PXS-4699) through to the start of human clinical trials.*Dual amine oxidase inhibitor*

PXS-4699 is a dual amine oxidase inhibitor which is expected to protect muscle and reduce inflammation as well as organ fibrosis in DMD.

Pharmaxis was selected following a highly competitive review conducted by an independent expert evaluation committee as part of the BTB program, which is administered by MTPConnect.

Full Article